Genmab's Phase 3 China DLBCL trial of epcoritamab posts results, listed active not recruitingNov 10Trial updateAbbVieepcoritamab-bysp
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphomaNov 9Regulatory decisionepcoritamab-bysp
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Genmab's EPCORE DLBCL-1 Phase 3 trial posts results after primary completion in October 2026Nov 3Trial updateAbbVieepcoritamab-bysp
AbbVie's AGN-151586 Phase 2 forehead lines study completes enrollment; four more trials registeredOct 8Weekly roundup, 5 itemsAbbVieAGN-151586Updated
AbbVie sponsors new ABBV-253 solid tumor trial; collaborates on epcoritamab lymphoma studySep 10Weekly roundup, 2 itemsABBV-253AbbVie
AbbVie to acquire Apogee Therapeutics, updates 2026 EPS guidance amid Q2 resultsJul 31Quarterly updateAbbVie
AbbVie week: BOTOX oral pain results post; new CLL, myeloma, ABBV-859 trials filedJul 31Weekly roundup, 6 itemsABBV-859AbbVie
Genmab reports positive Phase 3 results for epcoritamab plus lenalidomide in DLBCLJun 29Clinical readoutepcoritamab-byspGenmab A/S